Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: novel treatment predictive factors identified.

Green H, Stål O, Bachmeier K, Bäcklund LM, Carlsson L, Hansen J, Lagerlund M, Norberg B, Franzén Å, Åleskog A, Malmström A

Cancer Lett. 313 (2) 145-153 [2011-12-27; online 2011-08-31]

We investigated the efficacy and safety of single-agent pegylated liposomal doxorubicin (PLD) as first-line treatment for elderly women with advanced breast cancer and evaluated predictive markers for response and toxicity. Twenty-five women ≥ 65 years received 40 mg/m(2) PLD every 28 days. Time to treatment failure (TTF), response rate, time to progression (TTP) and overall survival (OS) was calculated. The ABCB1 single nucleotide polymorphisms (SNP), tumor MRN complex, and TOPOIIα were analyzed. A mean of 7.4 cycles PLD were administered and TTF was 5.5 months and OS 20.6 months. ABCB1 SNPs were found to correlate to both efficacy and toxicity, while tumor expression of the MRN complex and TOPOIIα correlated to TTP. PLD is a safe and effective treatment for elderly breast cancer patients. Also potential predictive markers were identified.

Affiliated researcher

PubMed 22056077

DOI 10.1016/j.canlet.2011.07.017

Crossref 10.1016/j.canlet.2011.07.017

pii: S0304-3835(11)00431-9

Publications 9.5.0